Quadrature Capital LTD Coherus Bio Sciences, Inc. Transaction History
Quadrature Capital LTD
- $8.45 Trillion
- Q3 2025
A detailed history of Quadrature Capital LTD transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Quadrature Capital LTD holds 18,172 shares of CHRS stock, worth $21,624. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,172Holding current value
$21,624% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
126Shares Held
54.7MCall Options Held
291KPut Options Held
120K-
Black Rock Inc. New York, NY11.8MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$6.07 Million0.38% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.61 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.74MShares$3.26 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $92.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...